RCT | Rucaparib vs. physician’s choice in metastatic prostate cancer

Summary: This phase 3 randomized trial compared Rucaparib vs. physician’s choice control (docetaxel or a second-generation ARPI) in treating metastatic, castration-resistant prostate cancer patients with a BRCA1, BRCA2, or ATM alteration who had disease progression after treatment with a second-generation androgen-receptor pathway inhibitor (ARPI). The study found that the duration of radiographic progression-free survival was significantly longer in the rucaparib group than in the control group. The most frequent adverse events with rucaparib were fatigue and nausea.

Article: Rucaparib or Physician’s Choice in Metastatic Prostate Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Rucaparib Efficacious in Metastatic Castration-Resistant Prostate Cancer – HealthDay

Commentary on Twitter

Original Article: Rucaparib or Physician’s Choice in Metastatic Prostate Cancer (TRITON3) https://t.co/vuHTxqRRyb#GU23 #oncology pic.twitter.com/UrPMOgW4Fo

— NEJM (@NEJM) February 17, 2023